Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3]. Financial Performance and Issues - Simulations Plus claimed successful integration of Pro-ficiency and effective internal controls over financial reporting, which appears to be misleading as the company struggled with integration and lacked effective controls [3]. - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing challenges to market uncertainties, leading to a stock price drop of over 24% [4]. - The Q3 2025 financial results included a $77.2 million charge related to prior acquisitions, and the company dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5]. Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5].

Core Viewpoint - Fluor Corporation is under investigation for potential violations of federal securities laws following the revelation of undisclosed issues in its infrastructure projects, leading to significant stock price declines [1][4]. Company Overview - Fluor Corporation is a global professional services firm that provides engineering, procurement and construction, fabrication and modularization, and project management services, operating through three main segments: Urban Solutions, Energy Solutions, and Mission Solutions [2]. Financial Performance and Issues - During the relevant period, Fluor claimed strong productivity in its infrastructure portfolio; however, several projects faced undisclosed design errors, delays, and price escalations that adversely affected the company's business [3]. - On August 1, 2025, Fluor reported disappointing fiscal Q2 2025 results, disclosing a $54 million net impact from cost growth and expected recoveries on three infrastructure projects due to subcontractor design errors, which led to a more than 30% drop in stock price on the same day [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Alto Neuroscience, Inc. regarding a class action lawsuit due to alleged misleading statements about the company's product pipeline and financial prospects [1][4]. Group 1: Class Action Details - The class action lawsuit is on behalf of all persons and entities that purchased Alto common stock during the class period from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment, although it is not required to partake in any recovery [1][5]. Group 2: Allegations - The complaint alleges that during the class period, the defendants made materially false and misleading statements regarding the effectiveness of the product ALTO-100 in treating major depressive disorder [4]. - It is claimed that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, leading to an inflated perception of Alto's business and financial prospects [4]. Group 3: Next Steps for Shareholders - Shareholders must register by September 19, 2025, to participate in the class action and will be enrolled in a portfolio monitoring software for updates on the case [5]. - There is no cost or obligation for shareholders to participate in the case [5]. Group 4: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered from deceit and fraud [6]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [6].

Core Viewpoint - J.M. Smucker Company is under investigation for potential violations of federal securities laws following significant impairment charges related to its Sweet Baked Snacks segment and the Hostess brand trademark, which have led to a substantial decline in stock price [1][3]. Group 1: Company Overview - J.M. Smucker manufactures and markets branded food and beverage products, including the recently acquired Hostess Brands, Inc., which specializes in sweet baked goods [2]. - The company characterized the Hostess acquisition as "highly complementary," suggesting positive underlying trends in the snacking category [2]. Group 2: Financial Performance - In Q4 2025, J.M. Smucker reported an $867 million impairment charge related to the goodwill of its Sweet Baked Snacks segment and a $113 million impairment charge for the Hostess brand trademark due to ongoing underperformance [3]. - Following the announcement of these impairment charges, J.M. Smucker's stock price dropped by $17.44, or over 18%, from $111.85 on June 9, 2025, to $94.41 on June 10, 2025 [3].

PHILADELPHIA, July 31, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating potential claims against Fiserv, Inc. (NYSE: FI) ("Fiserv" or the "Company") related to alleged securities law violations. This investigation follows the filing of a securities class action lawsuit against Fiserv and certain of its senior executives on behalf of investors who purchased the Company's securities between July 24, 2024 and July 22, 2025 (the "Class Period"). Investor Deadline: Investors ...

Group 1 - The core issue involves potential violations of federal securities laws by Simulations Plus, Inc. due to allegations of providing misleading business information to investors [1] - Simulations Plus reported third fiscal quarter sales of $20.4 million, missing the consensus estimate by approximately $500,000, and experienced a net loss of $67.3 million compared to a net income of $3.1 million in the same period of 2024 [3] - Following the negative financial report, Simulations Plus's stock price dropped by $4.70 per share, or 25.76%, closing at $12.97 per share on July 15, 2025 [3] Group 2 - Simulations Plus is a life sciences software and consulting company that provides advanced biosimulation tools and consulting services to pharmaceutical and biotechnology companies globally [2] - The company has implemented workforce reductions and cost-cutting measures as part of an operational restructuring plan initiated in June 2025 [3]

Core Viewpoint - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, with concerns regarding the sustainability of its sales growth driven by temporary trade inventory loading rather than genuine consumer demand [1][2]. Group 1: Company Overview - BellRing operates in the convenient nutrition category, primarily known for its brands Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders [2]. - The company reported that Premier Protein achieved an all-time high in household penetration and claimed strong demand across all channels, attributed to distribution expansion and promotional activities [2]. Group 2: Sales Growth and Market Reaction - The sales growth during the relevant period may not be sustainable, as it could have been influenced by temporary inventory loading at key retailers [2]. - On May 5, 2025, BellRing disclosed that several key retailers reduced their weeks of supply, which would negatively impact growth in Q3 2025. This announcement led to a significant stock price decline of $13.96 per share, or over 18%, dropping from $77.34 to $63.38 on May 6, 2025 [3].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Laser Photonics Corporation for possible violations of federal securities laws and unlawful business practices, encouraging affected investors to reach out for legal options [1][3]. Financial Disclosure Issues - On September 23, 2024, Laser Photonics announced that its previously issued financial statements for the year ended December 31, 2023, and the period ended June 30, 2024, should no longer be relied upon due to an overstatement of deferred revenue identified by its predecessor auditor, Fruci & Associates II, PLLC [3]. - Following this announcement, Laser Photonics' stock price dropped by $6.90 per share, or 36.7%, closing at $11.90 per share on September 25, 2024 [3]. Legal Assistance Offer - The law firm is reaching out to long-term stockholders of Laser Photonics who have suffered losses, offering assistance and information regarding their legal rights and potential claims [1][4]. Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation across state and federal courts [5].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Encompass Health Corporation due to allegations of violations of federal securities laws and unlawful business practices following negative reports about the company's hospital performance [1][3]. Group 1: Allegations and Impact - A New York Times article published on July 15, 2025, reported that Encompass's for-profit hospitals perform below average on key safety measures, with 34 facilities rated by Medicare as having significantly worse rates of potentially preventable readmissions [3]. - The article highlighted "alarming mistakes" that have led to patient fatalities, raising serious concerns about the company's operational practices [3]. - Following the publication of this article, Encompass's stock price dropped by $12.39, or 10.4%, closing at $107.28 per share, resulting in financial losses for investors [4]. Group 2: Legal Actions and Contact Information - Investors who purchased or acquired Encompass shares and suffered losses are encouraged to contact Bragar Eagel & Squire for discussions regarding their legal rights and potential claims [1][5]. - The law firm specializes in representing individual and institutional investors in complex litigation, indicating a focus on protecting shareholder interests [6].

Core Viewpoint - Centene Corporation experienced a significant decline in stock price following the release of disappointing Q2 2025 financial results, leading to a class action lawsuit from investors alleging misleading statements about the company's financial health and market conditions [1][2][4][5]. Financial Performance - Centene reported a GAAP diluted loss per share of -$0.51 for Q2 2025, primarily due to a reduction in the company's net 2025 Marketplace risk adjustment revenue transfer estimate [4]. - The company withdrew its 2025 financial guidance on July 1, 2025, after a review revealed lower-than-expected market growth and higher morbidity levels than previously assumed, resulting in a stock price drop of over 40% [6]. Legal Issues - A class action lawsuit, Lunstrum v. Centene Corporation, has been filed, representing investors who purchased Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934 [2][4]. - The lawsuit claims that Centene's leadership misled investors by presenting an overly optimistic view of the company's financial health, despite internal data indicating lower enrollment and higher morbidity rates [5][7]. Market Conditions - Centene's public statements had previously suggested expanding market share and robust business performance, particularly in serving underinsured and uninsured populations, which the lawsuit argues were not aligned with actual operational metrics [5][7]. - A preliminary analysis indicated that more than two-thirds of Centene's Marketplace share showed lower-than-expected enrollment, contradicting the company's optimistic reports [5].